Phase 2 N=30 Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Primary: Number of Patients Treated in Compliance With Protocol — 29 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=43 Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.
Nevi
Primary: Frequency of BRAF Mutations Among Nevi — 6; 19 BRAF mutations
Phase 2 N=53 Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
Ulcerative Colitis
Primary: Detected Intraepithelial Neoplasia — 0.2 Number of detected IN
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Phase 3 N=295 Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular Age-Related Macular Degeneration
Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants
N/A N=15 Neo-nervegenesis in Inguinal Hernia Implant ProFlor
Inguinal Hernia
Primary: Ingrowth of Newly Formed Nervous Elements Within Hernia Implant ProFlor — 999.75; 1044; 2094 μm^2 — p=0.028
Phase 2 N=17 Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Pigmented Villonodular Synovitis · Diffuse-type Giant Cell Tumor · Tenosynovial Giant Cell Tumor
Primary: Percentage of Participants With Progression Free Survival — 82 percentage of participants with PFS